Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2007

Euroscreen and Cephalon Extend GPCR Discovery Collaboration through 2009

  • Euroscreen extended the term of an agreement with Cephalon to collaborate on multiple drug discovery programs through 2009.

    Euroscreen and Cephalon initiated the collaboration in 2004 to discover and develop small molecule therapeutics focused upon central nervous system diseases and targeting GPCRs. The companies apply the AequoScreen™ proprietary functional assay technology in their efforts to generate novel small molecule leads across a broad range of GPCR targets.

    Under the terms of the agreement, Euroscreen will receive R&D payments and additional milestone payments for successful programs. Euroscreen retains rights to programs that are not pursued by Cephalon.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »